Meeting Milestones in nAMD and DME Management: What's New?
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Activity Description
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches have been developed to enable continuous dosing over extended time intervals. With the recent inclusion of novel therapeutic approaches into the current treatment algorithms for nAMD and DME, it is crucial that clinicians are aware of the supporting data for these therapies and best practices for the continued management of patients with the Port Delivery System. This monograph evaluates efficacious treatment approaches that lengthen dosing intervals and reduce reliance on frequent anti-VEGF injections in patients with nAMD or DME.
Target Audience
The intended audience for this activity is comprehensive ophthalmologists and other healthcare professionals involved in the management of patients with nAMD and DME.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Examine injectable regimens for the treatment of nAMD and DME that have exhibited exceptional efficacy when dosing intervals have been increased.
- Evaluate how new surgical interventions may change the treatment paradigm in patients with nAMD or DME.
Activity Chair
Judy E. Kim, MD, FARVO, FASRS
Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
Milwaukee, WI
Faculty
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist, Bay Area Retina Associates
Volunteer Faculty, CPMC
Walnut Creek, CA
Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Planners/Reviewers
Caroline R. Baumal, MD, FASRS
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Medical Writer
Valerie Zimmerman, PhD
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, June 10, 2023, to June 10, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Roger A. Goldberg, MD, MBA
Consultant: AbbVie, Annexon, Coherus, EyePoint, Genentech/Roche, Outlook Therapeutics, Regeneron, Zeiss
Speaker Contracted by Ineligible Company: Apellis, Biogen, Genentech/Roche
Independent Research Contractor: AffaMed, Allergan, Annexon, Apellis, Genentech/Roche, Ocuphire, Unity
Judy E. Kim, MD, FARVO, FASRS
Consultant: Alimera, Allergan, Apellis, Bausch + Lomb, Clearside, Genentech, Notal, Novartis, Outlook Therapeutics, Regeneron
Independent Research Contractor: Optos
Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, EyePoint, Genentech, Graybug, Kodiak, Regenxbio, Zeiss
Independent Research Contractor: Adverum, Allergan, Annexon, Apellis, EyePoint, Genentech, Graybug, Kodiak, Notal, Opthea, Regeneron, Regenxbio
Planners/Reviewers reports the following relevant financial relationship(s)
Caroline R. Baumal, MD, FASRS
Employee or Executive Role: Apellis*
Consultant: Alcon, EyePoint, Genentech, Novartis, Ocuphire, Regeneron, Regenxbio, Roche
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
*Planning for this activity occurred prior to the employment arrangement that began on January 5, 2023. Planner was removed from this program and onsite presentation.
Medical Writer reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
The articles in this activity were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Goldberg, Kim, and Regillo during a live CE seminar held on January 18, 2023. The content of this activity has been approved by each of the faculty individually as an accurate representation of their presentations.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com